Rein Therapeutics faces Nasdaq delisting notice after shares trade below $1 bid threshold
RNTX•Nasdaq notice over bid-price non-compliance
Rein Therapeutics received a Nasdaq notice of delisting risk on Aug. 21, 2026 due to a sub-$1 bid price.
Non-compliance was cited under Nasdaq Listing Rule 5550(a)(1) after 30 consecutive trading days below $1.
The deadline to regain compliance is Feb. 17, 2027, via at least a $1 closing bid for 10 consecutive business days.
Failure to cure could trigger suspension and delisting procedures; an additional compliance period is possible but not assured.
